Sanofi

An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition

Phase 1Recruiting14 people2 Oct 2026clinicaltrials.gov

NCT07624513

CollaboratorPhase 3Not yet recruiting720 people3 Jun 2026clinicaltrials.gov

NCT07600151

CollaboratorPhase 1/2Not yet recruiting220 people20 May 2026clinicaltrials.gov

NCT07479979

CollaboratorPhase 1/2Recruiting62 people18 Mar 2026clinicaltrials.gov

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Phase 3Recruiting942 people24 Sept 2025clinicaltrials.gov

NCT06762769

CollaboratorPhase 2Recruiting63 people8 Jan 2025clinicaltrials.gov

NCT06716424

Phase 4Completed105 people4 Dec 2024clinicaltrials.gov

NCT06686628

Phase 1Completed23 people13 Nov 2024clinicaltrials.gov

NCT06671587

Phase 4Recruiting678 people4 Nov 2024clinicaltrials.gov

NCT06517017

CollaboratorPhase 2Recruiting40 people24 Jul 2024clinicaltrials.gov

NCT06506812

CollaboratorPhase 4Completed466,320 people18 Jul 2024clinicaltrials.gov

NCT06356571

Phase 2Recruiting64 people10 Apr 2024clinicaltrials.gov

NCT06216158

CollaboratorPhase 3Active, not recruiting411 people22 Jan 2024clinicaltrials.gov

NCT06203912

CollaboratorPhase 1Completed3 people12 Jan 2024clinicaltrials.gov

NCT06111586

Phase 2Active, not recruiting197 people1 Nov 2023clinicaltrials.gov

NCT06019728

Phase 4Completed8 people31 Aug 2023clinicaltrials.gov

NCT05922501

CollaboratorPhase 2Recruiting50 people28 Jun 2023clinicaltrials.gov

NCT05804032

CollaboratorPhase 3Completed514 people7 Apr 2023clinicaltrials.gov

NCT05780151

CollaboratorPhase 4Completed107 people22 Mar 2023clinicaltrials.gov

NCT05704049

Phase 2Active, not recruiting118 people30 Jan 2023clinicaltrials.gov